Originally Posted by
blakecb
Mac, they have provided sales guidance - I posted it on a previous post... from the 2011 capital raising.
When one takes a look at the bio-med companies on the ASX, as I have done recently, PEB starts to look expensive. For example, AHZ which has strong prospects and are also just ramping their global marketing strategy already have FY revenue of $7mil and are at a >$100mil market cap vs PEB's $200mil market cap on no renevue.
That said, with no competition on the NZX, PEB may still do very well....certainly I think the first hint of good sales with send this price soaring.